Stoke Therapeutics, Inc. (STOK) Tops Q4 EPS by 37c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q4 EPS of ($0.18), $0.37 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $22.61 million versus the consensus estimate of $4.1 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• TPI Composites exits Chapter 11, acquired by Energy Capital Partners
• Morgan Stanley Resumes Victoria Secret (VSXY) at Overweight
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside